Stay updated on Nivolumab for IDH Mutant Gliomas Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for IDH Mutant Gliomas Clinical Trial page.

Latest updates to the Nivolumab for IDH Mutant Gliomas Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe site revision was updated from v3.6.5 to v3.6.6, indicating a software version bump. This likely reflects an internal update rather than a change to the study information shown on the page.SummaryDifference0.1%

- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedThe page now displays Revision: v3.6.5, replacing Revision: v3.6.4, indicating an updated version of the page. It reflects an internal update rather than a change to the study content or results.SummaryDifference0.1%

- Check52 days agoChange DetectedThe revision label on the page was updated from v3.6.3 to v3.6.4. This represents a minor software release and does not modify study information or core content.SummaryDifference0.1%

- Check73 days agoChange DetectedThe revision tag was updated from v3.6.2 to v3.6.3, signaling a behind-the-scenes software update. There are no indicated changes to study content or visible functionality based on the provided data.SummaryDifference0.1%

- Check80 days agoChange DetectedThe page now shows revision v3.6.2, replacing the previous v3.6.0. This indicates an update to the site’s underlying system or template, without changing the study details.SummaryDifference0.1%

- Check94 days agoChange DetectedThe page now states that no participants are being recruited anymore and updates the study duration references to up to 54 months. New sections for How to Read a Study Record, Common Questions, and How to Join a Study are added, and the Intervention/Treatment details are expanded.SummaryDifference0.9%

Stay in the know with updates to Nivolumab for IDH Mutant Gliomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for IDH Mutant Gliomas Clinical Trial page.